Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

This study tests a combination of two drugs — cemiplimab (an immunotherapy) and ziv-aflibercept (a drug that blocks blood vessel growth feeding the tumor) — for people with metastatic uveal melanoma, a rare type of eye cancer that has spread to other organs, as well as certain other advanced melanomas. **You may be eligible if...** - You have metastatic uveal melanoma (eye melanoma that has spread) - Or you have advanced cutaneous, mucosal, or unknown primary melanoma that has progressed after prior anti-PD-1 immunotherapy - You are 18 or older with a life expectancy of more than 3 months - You are in good overall health (ECOG 0 or 1) with measurable disease - Your kidney protein levels and heart function are within acceptable ranges **You may NOT be eligible if...** - You have very poor organ function - Your urine protein levels are too high (500 mg or more in 24 hours) - You have uncontrolled bleeding or a condition that puts you at high risk of bleeding - Your heart's pumping function is abnormal Talk to your doctor to see if this trial is right for you.